Prelude Therapeutics (PRLD) Cash from Investing Activities Growth (3y) (2022 - 2026)
Prelude Therapeutics (PRLD) Cash from Investing Activities Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Prelude Therapeutics | 322.24 Mn | 177.64 Mn | - | -22.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.13% |
| Dec 31, 2025 | -259.68% |
| Sep 30, 2025 | 22.88% |
| Jun 30, 2025 | -41.84% |
| Mar 31, 2025 | 640.74% |
| Dec 31, 2024 | 142.50% |
| Sep 30, 2024 | 26.85% |
| Jun 30, 2024 | 313.21% |
| Mar 31, 2024 | 222.89% |
| Dec 31, 2023 | 194.39% |
| Sep 30, 2023 | 348.97% |
| Jun 30, 2023 | -1,115.51% |
| Mar 31, 2023 | 510.01% |
| Dec 31, 2022 | 106.53% |